Research Analysts Set Expectations for PTGX FY2026 Earnings

Posted by Brian Himes on Aug 11th, 2026

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) – Research analysts at HC Wainwright cut their FY2026 earnings per share estimates for Protagonist Therapeutics in a research report issued to clients and investors on Thursday, August 6th. HC Wainwright analyst D. Tsao now expects that the company will earn $4.00 per share for the year, down from their prior forecast of $4.72. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $3.51 per share. HC Wainwright also issued estimates for Protagonist Therapeutics’ Q4 2026 earnings at ($0.90) EPS, FY2027 earnings at ($2.80) EPS, FY2028 earnings at ($2.45) EPS, FY2029 earnings at $0.12 EPS and FY2030 earnings at $1.46 EPS.

PTGX has been the topic of a number of other reports. The Goldman Sachs Group raised shares of Protagonist Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $110.00 to $186.00 in a research note on Monday. Weiss Ratings reissued a “sell (d+)” rating on shares of Protagonist Therapeutics in a research report on Friday, May 15th. Truist Financial raised their price target on shares of Protagonist Therapeutics from $145.00 to $170.00 and gave the company a “buy” rating in a research report on Monday. Wall Street Zen downgraded Protagonist Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Finally, Johnson Rice set a $165.00 price target on Protagonist Therapeutics in a research note on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $137.86.

View Our Latest Report on Protagonist Therapeutics

Protagonist Therapeutics Trading Up 2.8%

Shares of PTGX stock opened at $150.00 on Monday. The firm has a fifty day simple moving average of $125.41 and a two-hundred day simple moving average of $105.85. Protagonist Therapeutics has a 12 month low of $50.58 and a 12 month high of $151.60. The firm has a market capitalization of $9.65 billion, a PE ratio of 145.63 and a beta of 1.78.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.27 by $0.02. Protagonist Therapeutics had a return on equity of 12.03% and a net margin of 29.40%.The company had revenue of $213.47 million for the quarter, compared to analysts’ expectations of $212.03 million. The firm’s quarterly revenue was up 3746.8% on a year-over-year basis.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Farther Finance Advisors LLC grew its position in Protagonist Therapeutics by 110.6% in the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after purchasing an additional 156 shares in the last quarter. Greenline Wealth Management LLC bought a new position in shares of Protagonist Therapeutics during the 4th quarter worth approximately $27,000. Osaic Holdings Inc. lifted its position in shares of Protagonist Therapeutics by 79.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,185 shares of the company’s stock worth $65,000 after buying an additional 525 shares in the last quarter. Hantz Financial Services Inc. boosted its stake in shares of Protagonist Therapeutics by 222.4% in the 4th quarter. Hantz Financial Services Inc. now owns 951 shares of the company’s stock worth $83,000 after buying an additional 656 shares during the last quarter. Finally, Harbor Investment Advisory LLC purchased a new position in shares of Protagonist Therapeutics in the 2nd quarter worth approximately $89,000. 98.63% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Protagonist Therapeutics news, Director William D. Waddill sold 9,000 shares of Protagonist Therapeutics stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $117.94, for a total transaction of $1,061,460.00. Following the transaction, the director directly owned 7,825 shares of the company’s stock, valued at $922,880.50. The trade was a 53.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 27,000 shares of company stock worth $2,927,340. 5.19% of the stock is currently owned by company insiders.

About Protagonist Therapeutics

(Get Free Report)

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.